Roivant Sciences Ltd
ROIV
Company Profile
Business description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Contact
50 Broadway
7th Floor
LondonSW1H 0BD
GBRT: +44 2074003347
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
750
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks
ASX retail share expected to recover despite choppy conditions
Weakening consumer demand a temporary headwind for ASX retailer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.70 | 1.20 | -0.01% |
| CAC 40 | 8,112.57 | 89.51 | -1.09% |
| DAX 40 | 24,338.63 | 324.98 | -1.32% |
| Dow JONES (US) | 49,609.16 | 12.19 | 0.02% |
| FTSE 100 | 10,233.07 | 43.88 | -0.43% |
| HKSE | 26,318.37 | 75.34 | -0.29% |
| NASDAQ | 26,247.08 | 440.88 | 1.71% |
| Nikkei 225 | 62,684.35 | 29.30 | -0.05% |
| NZX 50 Index | 13,172.07 | 3.06 | -0.02% |
| S&P 500 | 7,398.93 | 61.82 | 0.84% |
| S&P/ASX 200 | 8,687.80 | 2.50 | -0.03% |
| SSE Composite Index | 4,219.13 | 39.18 | 0.94% |